Company: INCR
Filing Date: 2025-10-08
Form Type: 6-K
Source: 0001493152-25-017373
Chunk: 0

Company: Intercure Ltd.
Filing Date: 2025-10-08
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of October 2025

Commission File Number: 001-40614

INTERCURE LTD.

(Translation of registrant’s name into English)

85 Medinat ha-Yehudim Street

Herzliya, 4676670, Israel

Tel: +972 77 460 5012

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐</div>

This Report of Foreign Private Issuer on Form 6-K consists of InterCure Ltd.’s (the “Registrant”): (i)press release issued on October 8, 2025, titled “InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow,” which is attached hereto as Exhibit 99.1; (ii) Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2025, which is attached hereto as Exhibit 99.2; and (ii) Management’s Discussion and Analysis of Financial Condition and Results of Operationsas of June 30, 2025, and for the Six Months then Ended , which is attached hereto as Exhibit 99.3.

| Exhibit No. 
 99.1        
 99.2        |     | Press                                                                                                                                                         
 Release issued by InterCure Ltd. on October 8, 2025, titled “InterCure Reports First Half 2025 Results with NIS 130                                           
 Million in Revenue and Positive Operating Cash Flow.”                                                                                                         
 InterCure Ltd.’s Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2025.                                                           |
|:------------|:----|:--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 99.3        |     | InterCure Ltd.’s Management’s Discussion and Analysis of Financial Condition and Results of Operation as of June 30, 2025, and for the Six Months then Ended. |
| 101         |     | The following financial